当前位置： SCI文献检索 > IMMUNOLOGY期刊下所有文献 > Montelukast alleviates inflammation in experimental autoimmune encephalomyelitis by altering Th17 differentiation in a mouse model.

Montelukast alleviates inflammation in experimental autoimmune encephalomyelitis by altering Th17 differentiation in a mouse model.

Abstract：

:Montelukast is a leukotriene receptor antagonist that is known to prevent allergic rhinitis and asthma. Blocking the Cysteinyl leukotrienes receptor (CysLTR1), one of the primary receptors of leukotrienes, has been demonstrated to be efficacious in ameliorating experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), through disrupting chemotaxis of infiltrating T cells. However, the role of CysLTR1 in the pathogenesis of MS is not well understood. Here, we show that MS patients had higher expression of CysLTR1 in the circulation and central nervous system (CNS). The majority of CD4+ T cells expressed CysLTR1 in MS lesions. Among T cell subsets, Th17 cells had the highest expression of CysLTR1, and blocking CysLTR1 signaling abrogated their development in vitro. Inhibition of CysLTR1 by montelukast suppressed EAE development in both a prophylactic and therapeutic manner and inhibited myelin loss in EAE mice. Similarly, the in vivo results showed that montelukast inhibited Th17 response in EAE mice and that Th17 cells treated with montelukast had reduced encephalitogenic in adoptive EAE. Our findings strongly suggest that targeting Th17 response by inhibiting CysLTR1 signaling could be a promising therapeutic strategy for the treatment of MS and CNS inflammatory diseases.

journal_name

Immunology

journal_title

Immunology

authors

Han B,Zhang YY,Ye ZQ,Xiao Y,Rasouli J,Wu WC,Ye SM,Guo XY,Zhu L,Rostami A,Wang LB,Zhang Y,Li X

doi

10.1111/imm.13308

subject

Has Abstract

pub_date

2021-01-22 00:00:00

eissn

0019-2805

issn

1365-2567

pub_type

杂志文章

相关文献

IMMUNOLOGY文献大全